HGF Beta Chain Mutants Modulate c-Met Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The complexity of the HGF/Met signaling pathway, particularly in understanding HGF-HGF and HGF/Met interactions, has hindered the development of effective therapeutic means, necessitating a better comprehension of the mechanism of action to modulate this pathway effectively.
Innovation Solution
Designing HGF mutants with specific mutations in the β chain's N-terminal region and dimerization domain that impair signaling through the HGF/Met pathway, allowing for the creation of HGF/C-Met antagonist molecules that can inhibit wild-type HGF/HGF and HGF/c-Met interactions, thereby modulating biological functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If HGF mutants with specific mutations in the β chain's N-terminal region and dimerization domain are designed to impair signaling through the HGF/Met pathway, then the ability to modulate biological functions is improved, but the complexity of understanding HGF-HGF and HGF/Met interactions increases
Solution Approach 1:
The HGF molecule is segmented into functional domains (α-chain, β-chain, N-terminal region, dimerization domain) with specific mutations introduced in the β-chain to selectively impair signaling while preserving other functions. This segmentation allows independent manipulation of different functional regions to achieve precise modulation of biological activities.
Solution Approach 2:
Specific local mutations are introduced in the β-chain's N-terminal region and dimerization domain to create HGF variants with altered signaling properties. These localized changes affect only specific interactions (HGF-HGF and HGF/c-Met) while preserving overall structural integrity and other functional capabilities.
2Reliability
If HGF mutants are designed to compete with wild-type HGF for binding to c-Met, then therapeutic potential for conditions requiring reduced HGF/c-Met activity is improved, but the precision of controlling biological function inhibition deteriorates
Solution Approach 1:
Specific amino acid substitutions are introduced in the β-chain (e.g., R494E, R502E, R692E, R699E) to alter binding parameters and signaling efficiency. These parameter changes enable precise control over the degree of biological function inhibition, allowing therapeutic modulation rather than complete blockade.
Solution Approach 2:
The HGF mutants are designed to partially inhibit HGF/c-Met interactions rather than completely block them. This partial action provides therapeutic benefit by reducing excessive signaling in pathological conditions while maintaining sufficient activity for essential physiological functions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These mutant molecules effectively compete with wild-type HGF for binding to c-Met, reducing biological functions associated with the HGF/c-Met axis, providing therapeutic potential for conditions requiring reduced but not complete inhibition of HGF/c-Met activity.
Implementation Method 1
The protease-like domain of HGF (HGF β-chain) is devoid of catalytic activity since it lacks the required Asp [c102]-His [c57]-Ser [c195] (standard chymotrypsinogen numbering in brackets throughout) catalytic triad found in all serine proteases
Implementation Method 2
Acquisition of HGF signaling activity is contingent upon proteolytic cleavage (activation) of scHGF at Arg494-Val495 resulting in the formation of mature HGF, a disulfide-linked α/β heterodimer
Implementation Method 3
Acquisition of HGF signaling activity is contingent upon proteolytic cleavage (activation) of scHGF at Arg494-Val495 resulting in the formation of mature HGF, a disulfide-linked α/β heterodimer
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The invention provides HGF/Met modulators comprising HGF having mutations in regions that affect HGF function, and antagonists that target said regions. The invention further provides methods of identifying, making and using these modulators.